High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer
Abstract Background and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT). Methods and patients For all patients, the PIV was calculated using...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2023-12-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-023-00851-8 |
| _version_ | 1797388266707615744 |
|---|---|
| author | Erkan Topkan Ahmet Kucuk Emine Elif Ozkan Duriye Ozturk Ali Ayberk Besen Huseyin Mertsoylu Berrin Pehlivan Ugur Selek |
| author_facet | Erkan Topkan Ahmet Kucuk Emine Elif Ozkan Duriye Ozturk Ali Ayberk Besen Huseyin Mertsoylu Berrin Pehlivan Ugur Selek |
| author_sort | Erkan Topkan |
| collection | DOAJ |
| description | Abstract Background and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT). Methods and patients For all patients, the PIV was calculated using platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) measures obtained on the first day of CCRT: PIV = P × M × N ÷ L. Using receiver operating characteristic (ROC) curve analysis, we searched for the existence of an ideal cutoff that may partition patients into two groups with unique progression-free- (PFS) and overall survival (OS) results. The primary endpoint of this retrospective cohort research was to determine whether there were any significant relationships between pretreatment PIV measures and post-CCRT OS outcomes. Results The present research included a total of 807 stage IIIB/C NSCLC patients. According to ROC curve analysis, the ideal PIV cutoff was 516 [area under the curve (AUC): 67.7%; sensitivity: 66.4%; specificity: 66.1%], which divided the whole cohort into two: low PIV (L-PIV: PIV < 516; N = 436) and high PIV (H-PIV: PIV ≥ 516; N = 371). The comparisons between the PIV groups indicated that either the median PFS (9.2 vs. 13.4 months; P < 0.001) or OS (16.7 vs. 32.7 months; P < 0.001) durations in the H-PIV group were substantially inferior to their L-PIV counterpart. Apart from the H-PIV (P < 0.001), the N3 nodal stage (P = 0.006), IIIC disease stage (P < 0.001), and receiving only one cycle of concurrent chemotherapy (P = 0.005) were also determined to be significant predictors of poor PFS (P < 0.05, for each) and OS (P < 0.05, for each) outcomes in univariate analysis. The multivariate analysis findings revealed that all four variables had independent negative impacts on PFS (P < 0.05, for each) and OS (P < 0.05, for each). Conclusions The findings of this hypothesis-generating retrospective analysis claimed that the novel PIV was an independent and steadfast predictor of PFS and OS in stage IIIB/C NSCLC patients. |
| first_indexed | 2024-03-08T22:37:19Z |
| format | Article |
| id | doaj.art-630d2705d8d24ccb9ddafca6f63a85f8 |
| institution | Directory Open Access Journal |
| issn | 2730-6011 |
| language | English |
| last_indexed | 2024-03-08T22:37:19Z |
| publishDate | 2023-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj.art-630d2705d8d24ccb9ddafca6f63a85f82023-12-17T12:21:32ZengSpringerDiscover Oncology2730-60112023-12-0114111110.1007/s12672-023-00851-8High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancerErkan Topkan0Ahmet Kucuk1Emine Elif Ozkan2Duriye Ozturk3Ali Ayberk Besen4Huseyin Mertsoylu5Berrin Pehlivan6Ugur Selek7Department of Radiation Oncology, Baskent University Medical FacultyClinic of Radiation Oncology, Mersin Education and Research HospitalDepartment of Radiation Oncology, Suleyman Demirel UniversityDepartment of Radiation Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences UniversityDepartment of Medical Oncology, Medical Park HospitalDepartment of Medical Oncology, Istinye UniversityDepartment of Radiation Oncology, Bahcesehir UniversityDepartment of Radiation Oncology, Koc University School of MedicineAbstract Background and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT). Methods and patients For all patients, the PIV was calculated using platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) measures obtained on the first day of CCRT: PIV = P × M × N ÷ L. Using receiver operating characteristic (ROC) curve analysis, we searched for the existence of an ideal cutoff that may partition patients into two groups with unique progression-free- (PFS) and overall survival (OS) results. The primary endpoint of this retrospective cohort research was to determine whether there were any significant relationships between pretreatment PIV measures and post-CCRT OS outcomes. Results The present research included a total of 807 stage IIIB/C NSCLC patients. According to ROC curve analysis, the ideal PIV cutoff was 516 [area under the curve (AUC): 67.7%; sensitivity: 66.4%; specificity: 66.1%], which divided the whole cohort into two: low PIV (L-PIV: PIV < 516; N = 436) and high PIV (H-PIV: PIV ≥ 516; N = 371). The comparisons between the PIV groups indicated that either the median PFS (9.2 vs. 13.4 months; P < 0.001) or OS (16.7 vs. 32.7 months; P < 0.001) durations in the H-PIV group were substantially inferior to their L-PIV counterpart. Apart from the H-PIV (P < 0.001), the N3 nodal stage (P = 0.006), IIIC disease stage (P < 0.001), and receiving only one cycle of concurrent chemotherapy (P = 0.005) were also determined to be significant predictors of poor PFS (P < 0.05, for each) and OS (P < 0.05, for each) outcomes in univariate analysis. The multivariate analysis findings revealed that all four variables had independent negative impacts on PFS (P < 0.05, for each) and OS (P < 0.05, for each). Conclusions The findings of this hypothesis-generating retrospective analysis claimed that the novel PIV was an independent and steadfast predictor of PFS and OS in stage IIIB/C NSCLC patients.https://doi.org/10.1007/s12672-023-00851-8Non-small-cell lung cancerInflammationBiological markerPan-immune-inflammation valuePrognosis survival |
| spellingShingle | Erkan Topkan Ahmet Kucuk Emine Elif Ozkan Duriye Ozturk Ali Ayberk Besen Huseyin Mertsoylu Berrin Pehlivan Ugur Selek High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer Discover Oncology Non-small-cell lung cancer Inflammation Biological marker Pan-immune-inflammation value Prognosis survival |
| title | High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer |
| title_full | High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer |
| title_fullStr | High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer |
| title_full_unstemmed | High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer |
| title_short | High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer |
| title_sort | high pre chemoradiotherapy pan immune inflammation value levels predict worse outcomes in patients with stage iiib c non small cell lung cancer |
| topic | Non-small-cell lung cancer Inflammation Biological marker Pan-immune-inflammation value Prognosis survival |
| url | https://doi.org/10.1007/s12672-023-00851-8 |
| work_keys_str_mv | AT erkantopkan highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer AT ahmetkucuk highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer AT emineelifozkan highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer AT duriyeozturk highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer AT aliayberkbesen highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer AT huseyinmertsoylu highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer AT berrinpehlivan highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer AT ugurselek highprechemoradiotherapypanimmuneinflammationvaluelevelspredictworseoutcomesinpatientswithstageiiibcnonsmallcelllungcancer |